MedTrace Logo

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

NCT00304018 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2013-08-14

No results posted yet for this study

Summary

RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and etoposide, before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving antithymocyte globulin before transplant and tacrolimus and prednisone after transplant may stop this from happening.

PURPOSE: This phase I trial is studying how well donor umbilical cord blood transplant works in treating patients with advanced hematologic cancer.

Conditions

Interventions

BIOLOGICAL

anti-thymocyte globulin

BIOLOGICAL

sargramostim

DRUG

busulfan

DRUG

etoposide

DRUG

fludarabine phosphate

DRUG

prednisone

DRUG

tacrolimus

PROCEDURE

allogeneic hematopoietic stem cell transplantation

PROCEDURE

umbilical cord blood transplantation

Sponsors & Collaborators

Principal Investigators

  • Thomas G. Martin, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00304018 on ClinicalTrials.gov